AdventHealth Central Florida Division Medical Director of Neonatology Appointed to Serve as Florida Representative of Hospitals

Dr. Dereddy

Narendra Dereddy, MD, was appointed to the Board of Directors of the Florida Birth-Related Neurological Injury Compensation Association (NICA) and will serve as the Florida representative of hospitals.

Dereddy currently serves as the medical director for neonatology, the neonatal intensive care unit, and pediatric care transformation at AdventHealth.

Created by Florida legislature in response to the malpractice insurance crisis where obstetricians were reluctant to treat high risk pregnancies, NICA is responsible for providing medically necessary help to infants affected by catastrophic birth-related neurologic injuries. The statutory organization manages state funds collected from participating physicians and hospitals to provide appropriate medical care and assistance to these infants and their families.

“As a neonatal-perinatal medicine specialist, I have cared for hundreds of infants affected by various birth related neurologic injuries and wanted to serve on the NICA board to advocate for these vulnerable infants and support preventive measures to decrease the incidence of birth-related neurologic injuries,” Dereddy said.

Dereddy attended medical school at Banaras Hindu University in India and completed his residency and fellowship at Maria Fareri Children’s Hospital at Westchester Medical Center at New York Medical College. Additionally, he is a member of the American Academy of Pediatrics.

Dereddy is one of several AdventHealth clinical leaders who have been recently appointed to a statewide post. He will serve in this position through August 2024.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
New England Journal of Medicine highlights Guru Sonpavde, MD’s work in new immunotherapy-chemotherapy combination improving survival for patients with advanced urothelial carcinoma

The CheckMate 901 Phase III clinical trial results, recently published in the New England Journal of Medicine, found that combining the programmed death 1 (PD1) inhibitor immunotherapy nivolumab with...

Read Article about "New England Journal of Medicine highlights Guru Sonpavde, MD’s work in new immunotherapy-chemotherapy combination improving survival for patients with advanced urothelial carcinoma"
View More Articles